Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The event, scheduled for September 16 at 8:30 a.m. EDT, will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at one of the most prominent healthcare investment conferences underscores Helus Pharma's growing visibility in the biopharmaceutical sector. Morgan Stanley's Global Healthcare Conference attracts top executives, investors, and analysts, providing a platform for companies to showcase their pipelines and strategic visions. For Helus Pharma, this fireside chat represents an opportunity to engage with potential investors and partners, potentially boosting its profile as it advances its clinical programs.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the significant unmet need for effective treatments for depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that offer durable improvements in mental health.
The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is reserved for drugs that may offer substantial improvement over existing therapies, highlighting the potential of HLP003. Additionally, HLP004 is in Phase 2 development for generalized anxiety disorder, further expanding Helus Pharma's pipeline. The company also maintains an extensive research portfolio of investigational NSAs.
Operating in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is positioning itself as a key player in the mental health therapeutics space. For more information and company updates, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
The participation in the Morgan Stanley conference comes at a critical time for Helus Pharma as it continues to advance its clinical trials and seeks to differentiate itself in a competitive landscape. Mental health disorders affect millions worldwide, and the need for innovative treatments is urgent. Helus Pharma's focus on NSAs could offer new hope for patients who have not responded to existing therapies. The fireside chat will allow investors to gain insights into the company's strategy, upcoming milestones, and the potential of its pipeline.
As the conference date approaches, stakeholders will be watching closely for any updates on Helus Pharma's progress. The webcast and replay will ensure that interested parties can access the discussion, further extending the reach of the company's message. With its innovative approach and late-stage assets, Helus Pharma is well-positioned to make a meaningful impact in the treatment of mental health conditions.
